Title: OPD management of Peripheral Arterial Disease patients in a Tertiary Care hospital: Does Aspirin and Cilostazol help
Authors: Nadeem Ul Nazeer, Ghulam Nabi Lone, Farooq A Ganie, Mohammad Akbar Bhat, Abdul Majeed Dar, Hakeem Zubair Ashraf, Syed Abdul Wahid, Haroon R Naqshi, Mosin Mushtaq
Background: Cilostazol is the first-line drug for peripheral arterial disease (PAD) because it improves the symptoms and quality of life. The treatment of PAD involves the prevention of cardiovascular events plus relief of symptoms including intermittent claudication (IC). The objective of this study was to evaluate the efficacy of aspirin and cilostazol in patients suffering from peripheral arterial disease (PAD).
Methods: Patients were evaluated on outpatient department (OPD) basis. Meticulous history was followed by clinical examination and measurement of ankle-brachial index for diagnosing PAD. The patients also underwent duplex imaging, computed tomography angiography or magnetic resonance angiography. The treatment includes lifestyle modification in the form of smoking cessation and exercise; management of atherosclerotic risk factors, including antiplatelets, statins, drugs for hypertension; and agents to improve walking distance, such as cilostazol and enalapril
Results: The mean age of the patients was 47±6.2 years. History of smoking, either past or current, was present in 91% of patients. History of ischemic heart disease was present in 2.17 %, while 26.08% patients were diabetic. Aspirin and cilostazol were prescribed after the diagnosis was made. Symptomatically, all the patients improved. Walking time was improved in all the patients.
Conclusion: The safety proﬁle of aspirin and cilostazol in patients with PAD appears to be acceptable. In addition to risk factor management, treatment with cilostazol should be considered in patients of PAD.
Keywords: OPD, aspirin, cilostazol, peripheral arterial disease, management.